KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Income from Non-Controlling Interests (2016 - 2025)

Teva Pharmaceutical Industries filings provide 17 years of Income from Non-Controlling Interests readings, the most recent being $1.0 million for Q3 2025.

  • On a quarterly basis, Income from Non-Controlling Interests fell 97.87% to $1.0 million in Q3 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 102.19% increase, with the full-year FY2025 number at $7.0 million, up 102.19% from a year prior.
  • Income from Non-Controlling Interests hit $1.0 million in Q3 2025 for Teva Pharmaceutical Industries, down from $6.0 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $47.0 million in Q3 2024 to a low of -$280.0 million in Q1 2024.
  • Median Income from Non-Controlling Interests over the past 5 years was $3.0 million (2022), compared with a mean of -$21.3 million.
  • The widest YoY moves for Income from Non-Controlling Interests: up 487.5% in 2024, down 1550.0% in 2024.
  • Teva Pharmaceutical Industries' Income from Non-Controlling Interests stood at $7.0 million in 2021, then plummeted by 557.14% to -$32.0 million in 2022, then surged by 112.5% to $4.0 million in 2023, then plummeted by 1550.0% to -$58.0 million in 2024, then surged by 101.72% to $1.0 million in 2025.
  • The last three reported values for Income from Non-Controlling Interests were $1.0 million (Q3 2025), $6.0 million (Q1 2025), and -$58.0 million (Q4 2024) per Business Quant data.